Alpha-Methylacyl-CoA Racemase: A Novel Tumor Marker Over-expressed in Several Human Cancers and Their Precursor Lesions

&agr;-Methylacyl-CoA racemase (AMACR) is a mitochondrial and peroxisomal enzyme involved in the metabolism of branched-chain fatty acid and bile acid intermediates. Recently, AMACR has been demonstrated to be over-expressed in localized and metastatic prostate cancer, suggesting that it may be an important tumor marker. This study examines AMACR expression in a variety of human cancers and their precursor lesions. A survey of online Expressed Sequence Tags (ESTs) and Serial Analysis of Gene Expression (SAGE) databases revealed that AMACR was over-expressed in multiple cancers. The findings were confirmed by AMACR immunohistochemistry performed on several tissue microarrays containing common human tumors, including prostate, colon, and breast. Based on prior work, AMACR protein expression was divided into two categories: negative (negative to weak staining intensity) and positive (moderate to strong staining intensity). AMACR protein over-expression was found in a number of cancers, including colorectal, prostate, ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma. Greatest over-expression was seen in colorectal and prostate cancer with positive staining in 92% and 83% cases, respectively. AMACR over-expression was present in 44% of breast cancer cases. AMACR was also over-expressed in precursor lesions. Sixty-four percent of high-grade prostatic intraepithelial neoplasia and 75% colonic adenomas demonstrated positive AMACR protein expression. Reverse transcriptase-polymerase chain reaction for AMACR using laser capture microdissected prostate tissue confirmed gene over-expression at the mRNA level. In conclusion, our study suggests that AMACR is potentially an important tumor marker for several cancers and their precursor lesions, especially those linked to high-fat diets.

[1]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[2]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.

[3]  J. Trent,et al.  Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. , 2002, Cancer research.

[4]  S. Reed,et al.  P504S: A New Molecular Marker for the Detection of Prostate Carcinoma , 2001, The American journal of surgical pathology.

[5]  W. Gage,et al.  p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. , 2001, Urology.

[6]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[7]  R. Shah,et al.  Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? , 2001, The American journal of pathology.

[8]  P. Clayton.  Clinical consequences of defects in peroxisomal β-oxidation , 2001 .

[9]  Gerbert A. Jansen,et al.  Peroxisomal fatty acid α- and β-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases , 2001 .

[10]  P. Clayton.  Clinical consequences of defects in peroxisomal beta-oxidation. , 2001, Biochemical Society transactions.

[11]  Rajnish A. Gupta,et al.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.

[12]  P. Vreken,et al.  Peroxisomal fatty acid alpha- and beta-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases. , 2001, Biochemical Society transactions.

[13]  J. Auwerx,et al.  The pleiotropic functions of peroxisome proliferator-activated receptor γ , 2001, Journal of Molecular Medicine.

[14]  P. Vreken,et al.  Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy , 2001 .

[15]  R. Wanders,et al.  Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. , 2000, Journal of lipid research.

[16]  S. Ferdinandusse,et al.  Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. , 2000, Journal of lipid research.

[17]  G. Mannaerts,et al.  Mitochondrial and peroxisomal targeting of 2-methylacyl-CoA racemase in humans. , 2000, Journal of lipid research.

[18]  M. Carey,et al.  Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Cancer research.

[19]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Reddy,et al.  Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. , 2000, Mutation research.

[21]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[22]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  H. Bartsch,et al.  Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. , 1999, Carcinogenesis.

[24]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[25]  R. Zarbo,et al.  Diagnostic uncertainty expressed in prostate needle biopsies. A College of American Pathologists Q-probes Study of 15,753 prostate needle biopsies in 332 institutions. , 1999, Archives of pathology & laboratory medicine.

[26]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[27]  T. Miki,et al.  Utility of Immunohistochemical Detection of High Molecular Weight Cytokeratin for Differential Diagnosis of Proliferative Conditions of the Prostate , 1998, International journal of urology : official journal of the Japanese Urological Association.

[28]  R. Evans,et al.  Activators of the nuclear receptor PPARgamma enhance colon polyp formation. , 1998, Nature medicine.

[29]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[30]  J. Epstein.  The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens , 1996, Cancer.

[31]  L. Liotta,et al.  Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.

[32]  J. Epstein,et al.  Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. , 1995, Urology.

[33]  D. Shibata,et al.  Further evidence that one of the earliest alterations in colorectal carcinogenesis involves APC. , 1994, The American journal of pathology.

[34]  R. Fingerhut,et al.  Purification and properties of an alpha-methylacyl-CoA racemase from rat liver. , 1994, European journal of biochemistry.

[35]  D. Bostwick,et al.  Prostatic Intra‐Epithelial Neoplasia and Early Invasion in Prostate Cancer , 1987, Cancer.

[36]  T. Stamey,et al.  PATTERNS OF PROGRESSION IN PROSTATE CANCER , 1986, The Lancet.

[37]  D. Bostwick,et al.  Intraductal dysplasia: a premalignant lesion of the prostate. , 1986, Human pathology.